Novavax (NVAX) Revenue & Revenue Breakdown
Novavax Revenue Highlights
Latest Revenue (Y)
$983.71M
Latest Revenue (Q)
$93.86M
Main Segment (Y)
Product
Main Geography (Y)
Europe
Novavax Revenue by Period
Novavax Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $983.71M | -38.48% |
| 2022-12-31 | $1.60B | 39.49% |
| 2021-12-31 | $1.15B | 141.02% |
| 2020-12-31 | $475.60M | 2448.48% |
| 2019-12-31 | $18.66M | -45.57% |
| 2018-12-31 | $34.29M | 9.98% |
| 2017-12-31 | $31.18M | 103.06% |
| 2016-12-31 | $15.35M | -57.65% |
| 2015-12-31 | $36.25M | 18.24% |
| 2014-12-31 | $30.66M | 46.59% |
| 2013-12-31 | $20.91M | -5.26% |
| 2012-12-31 | $22.08M | 50.30% |
| 2011-12-31 | $14.69M | 4182.22% |
| 2010-12-31 | $343.00K | 5.54% |
| 2009-12-31 | $325.00K | -69.45% |
| 2008-12-31 | $1.06M | -29.68% |
| 2007-12-31 | $1.51M | -67.69% |
| 2006-12-31 | $4.68M | -36.61% |
| 2005-12-31 | $7.39M | -10.56% |
| 2004-12-31 | $8.26M | -29.91% |
| 2003-12-31 | $11.79M | -21.46% |
| 2002-12-31 | $15.01M | -37.65% |
| 2001-12-31 | $24.07M | 872.36% |
| 2000-12-31 | $2.48M | 106.25% |
| 1999-12-31 | $1.20M | 71.43% |
| 1998-12-31 | $700.00K | 40.00% |
| 1997-12-31 | $500.00K | 400.00% |
| 1996-12-31 | $100.00K | - |
Novavax generated $983.71M in revenue during NA 2023, up -38.48% compared to the previous quarter, and up 2868.95% compared to the same period a year ago.
Novavax Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $93.86M | -67.79% |
| 2023-12-31 | $291.34M | 1220.44% |
| 2023-09-30 | $22.06M | -94.80% |
| 2023-06-30 | $424.43M | 424.30% |
| 2023-03-31 | $80.95M | -71.88% |
| 2022-12-31 | $287.83M | -60.82% |
| 2022-09-30 | $734.58M | 295.09% |
| 2022-06-30 | $185.93M | -73.59% |
| 2022-03-31 | $703.97M | 216.82% |
| 2021-12-31 | $222.20M | 24.24% |
| 2021-09-30 | $178.84M | -39.99% |
| 2021-06-30 | $298.02M | -33.36% |
| 2021-03-31 | $447.23M | 59.92% |
| 2020-12-31 | $279.66M | 78.10% |
| 2020-09-30 | $157.02M | 341.85% |
| 2020-06-30 | $35.54M | 952.35% |
| 2020-03-31 | $3.38M | -61.69% |
| 2019-12-31 | $8.82M | 251.66% |
| 2019-09-30 | $2.51M | -25.32% |
| 2019-06-30 | $3.36M | -15.70% |
| 2019-03-31 | $3.98M | -35.01% |
| 2018-12-31 | $6.13M | -20.79% |
| 2018-09-30 | $7.74M | -28.20% |
| 2018-06-30 | $10.77M | 11.60% |
| 2018-03-31 | $9.65M | -7.29% |
| 2017-12-31 | $10.41M | 24.66% |
| 2017-09-30 | $8.35M | 24.06% |
| 2017-06-30 | $6.73M | 18.52% |
| 2017-03-31 | $5.68M | 5.20% |
| 2016-12-31 | $5.40M | 67.10% |
| 2016-09-30 | $3.23M | 28.98% |
| 2016-06-30 | $2.50M | -40.61% |
| 2016-03-31 | $4.22M | -27.93% |
| 2015-12-31 | $5.85M | -10.30% |
| 2015-09-30 | $6.53M | -53.38% |
| 2015-06-30 | $14.00M | 41.70% |
| 2015-03-31 | $9.88M | 46.89% |
| 2014-12-31 | $6.72M | -18.14% |
| 2014-09-30 | $8.21M | -0.54% |
| 2014-06-30 | $8.26M | 10.68% |
| 2014-03-31 | $7.46M | -14.70% |
| 2013-12-31 | $8.75M | 82.17% |
| 2013-09-30 | $4.80M | 36.00% |
| 2013-06-30 | $3.53M | -7.88% |
| 2013-03-31 | $3.83M | -16.05% |
| 2012-12-31 | $4.57M | -20.80% |
| 2012-09-30 | $5.76M | -18.84% |
| 2012-06-30 | $7.10M | 53.02% |
| 2012-03-31 | $4.64M | -20.58% |
| 2011-12-31 | $5.84M | 16.71% |
| 2011-09-30 | $5.01M | 66.88% |
| 2011-06-30 | $3.00M | 259.83% |
| 2011-03-31 | $834.00K | 1535.29% |
| 2010-12-31 | $51.00K | -70.86% |
| 2010-09-30 | $175.00K | 2400.00% |
| 2010-06-30 | $7.00K | -93.64% |
| 2010-03-31 | $110.00K | 48.65% |
| 2009-12-31 | $74.00K | -63.18% |
| 2009-09-30 | $201.00K | 593.10% |
| 2009-06-30 | $29.00K | 38.10% |
| 2009-03-31 | $21.00K | -70.00% |
| 2008-12-31 | $70.00K | -63.92% |
| 2008-09-30 | $194.00K | -43.27% |
| 2008-06-30 | $342.00K | -25.33% |
| 2008-03-31 | $458.00K | -172.81% |
| 2007-12-31 | $-629.00K | - |
Novavax generated $93.86M in revenue during Q1 2024, up -67.79% compared to the previous quarter, and up 32.61% compared to the same period a year ago.
Novavax Revenue Breakdown
Novavax Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Grant | $427.32M | $258.35M | $11.16M | - | - |
| Royalties and Other | $24.99M | $43.99M | $197.58M | - | - |
| Product | $531.39M | - | - | - | - |
| Sales-Based Royalties | - | $9.00M | $178.60M | - | - |
| Government Contract | - | - | - | $217.25M | $7.50M |
Novavax's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (54.02%), Grant (43.44%), and Royalties and Other (2.54%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | - | $37.94M | $164.92M | $137.08M | $87.38M | $105.66M | $35.54M | $3.38M | $1.32M | $2.51M | $3.36M | $3.98M | - | - | - | - | - | - | - |
| Royalties and Other | $11.53M | $1.95M | $19.83M | $2.18M | $1.03M | $39.00K | $2.21M | $22.70M | $19.04M | - | - | - | - | - | - | - | - | - | - |
| Product | $82.32M | $529.16M | $2.23M | $287.79M | $626.09M | $55.45M | $585.63M | - | - | - | - | - | - | - | - | - | - | - | - |
| Sales-Based Royalties | - | - | - | - | - | $-1.50M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | - | - | - | - | $39.94M | $23.46M | - | - | - | - | - | - | - | - |
| Government Contract | - | - | - | - | - | - | - | - | - | - | - | $140.00M | $1.62B | - | - | - | - | - | - |
Novavax's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (87.71%), and Royalties and Other (12.29%).
Novavax Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| Europe | $268.36M | $823.54M |
| Rest of the World | $233.07M | $536.94M |
| North America | $29.96M | $194.48M |
Novavax's latest annual revenue breakdown by geography, as of Dec 23: Europe (50.50%), Rest of the World (43.86%), and North America (5.64%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|
| Rest of the World | $-1.73M | $14.15M | - | $283.64M | $-64.72M |
| Europe | $90.42M | $209.58M | - | $1.52M | $57.27M |
| North America | $-6.36M | $27.73M | $2.23M | - | - |
Novavax's latest quarterly revenue breakdown by geography, as of Mar 24: Europe (109.83%), Rest of the World (-2.10%), and North America (-7.73%).
NVAX Revenue FAQ
What is Novavax’s yearly revenue?
Novavax's yearly revenue for 2023 was $983.7M, representing a decrease of -38.48% compared to 2022. The company's yearly revenue for 2022 was $1.6B, representing an increase of 39.49% compared to 2021. NVAX's yearly revenue for 2021 was $1.15B, representing an increase of 141.02% compared to 2020.
What is Novavax’s quarterly revenue?
Novavax's quarterly revenue for Q1 2024 was $93.86M, a -67.79% decrease from the previous quarter (Q4 2023), and a 15.94% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $291.34M, a 1220.44% increase from the previous quarter (Q3 2023), and a 1.22% increase year-over-year (Q4 2022). NVAX's quarterly revenue for Q3 2023 was $22.06M, a -94.80% decrease from the previous quarter (Q2 2023), and a -97.00% decrease year-over-year (Q3 2022).
What is Novavax’s revenue growth rate?
Novavax's revenue growth rate for the last 3 years (2021-2023) was -14.18%, and for the last 5 years (2019-2023) was 5171.17%.
What are Novavax’s revenue streams?
Novavax's revenue streams in c 23 are Grant, Royalties and Other, and Product. Grant generated $427.32M in revenue, accounting 43.44% of the company's total revenue, up 65.40% year-over-year. Royalties and Other generated $24.99M in revenue, accounting 2.54% of the company's total revenue, down -43.18% year-over-year. Product generated $531.39M in revenue, accounting 54.02% of the company's total revenue
What is Novavax’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Novavax was Product. This segment made a revenue of $531.39M, representing 54.02% of the company's total revenue.